Severe sporotrichoid fish tank granuloma following infliximab therapy

American Journal of Clinical Dermatology

Volumn 8, Issue 6, 2007, Pages 385-388

  Rallis, Efstathios ^a,d   Koumantaki Mathioudaki, Elma ^b   Frangoulis, Effie ^c   Chatziolou, Eftihia ^c   Katsambas, Andreas ^b  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ANDREAS SYGROS HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

Ethambutol, therapeutic use; Granuloma, general; Infliximab, therapeutic use; Isoniazid, therapeutic use; Rifampicin, therapeutic use

Indexed keywords

ETHAMBUTOL; INFLIXIMAB; ISONIAZID; RIFAMPICIN;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG EFFICACY; GRANULOMA; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MALE; MYCOBACTERIUM MARINUM; PRIORITY JOURNAL; SPOROTRICHOSIS; TUBERCULOSIS;

EID: 36448970501     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708060-00009     Document Type: Article

References (20)

1. Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 2006; 25: 609-13
2. Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162: 1746-52
3. Bartralot R, Garcia-Patos V, Sitjas D, et al. Clinical patterns of cutaneous non-tuberculous mycobacterial infections. Br J Dermatol 2005; 152: 727-34
4. Mufti AH, Toye BW, Mckendry RR, et al. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 2005; 53: 233-8
5. Clegg DO. Treatment of ankylosing spondylitis. J Rheumatol Suppl 2006; 78: 24-31
6. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55
7. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15): 1098-104
8. Wu TS, Chiu CH, Su LH, et al. Mycobacterium marinum infection in Taiwan. J Microbiol Immunol Infect 2002; 35: 42-6
9. Ang P, Rattana-Apiromyakij N, Goh CL. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 2000; 39: 343-7
10. Gbery IP, Djeha D, Yobouet P, et al. Atypical mycobacterial skin infections. Sante 1996; 6 (5): 317-22
11. Gluckman SJ. Mycobacterium marinum. Clin Dermatol 1995; 13: 273-6
12. Lim YW, Chia J, Looi KP. A case report of Mycobacterium marinum infection of the hand. Singapore Med J 2000; 41: 221-3
13. Lahey T. Invasive Mycobacterium marinum infections. Emerg Infect Dis 2003; 9 (11): 1496-8
14. Harth M, Ralph ED, Faraawi R. Septic arthritis due to Mycobacterium marinum. J Rheumatol 1994; 21 (5): 957-60
15. Chopra N, Kirschenbaum AE, Widman D. Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 2002; 8: 265-8
16. Lam A, Toma W, Schlesinger N. Mycobacterium marinum arthritis mimicking rheumatoid arthritis. J Rheumatol 2006; 33 (4): 817-9
17. Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29: 185-202
18. Peno-Green L, Lluberas G, Kingsley T, et al. Lung injury linked to etanercept therapy. Chest 2002; 122 (5): 1858-60
19. Phillips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002; 47 (1): 17-21
20. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38 (9): 1261-5